What's Happening?
Sky Labs has unveiled its CART BP pro, a ring-type cuffless blood pressure monitor, at the 9th Digital Biomarkers in Clinical Trials Summit in Basel, Switzerland. The device aims to address the limitations of traditional cuff-type ambulatory blood pressure monitoring
devices, which often cause discomfort and disrupt sleep, leading to increased dropout rates in clinical trials. The CART BP pro, worn on the finger, allows for continuous blood pressure monitoring without the need for arm constriction, thus providing stable, long-term vital signs data. This innovation is expected to enhance the collection of Real-World Evidence (RWE) data, crucial for evaluating drug efficacy and safety. The device is already in use in South Korea, supported by the national health insurance system and recommended by the Korean Guidelines for the Management of Hypertension.
Why It's Important?
The introduction of the CART BP pro by Sky Labs represents a significant advancement in clinical trial methodologies. By reducing the discomfort associated with traditional blood pressure monitoring, the device could lower dropout rates and improve data reliability in clinical trials. This is particularly important for pharmaceutical companies seeking to gather accurate RWE data to support drug development and regulatory submissions. The device's ability to monitor blood pressure continuously and non-invasively could also lead to better patient compliance and more comprehensive data collection, ultimately enhancing the evaluation of therapeutic responses and patient outcomes.
What's Next?
Sky Labs plans to expand the use of CART BP pro in clinical trials through strategic collaborations with global pharmaceutical companies. The company aims to position itself as a key partner in providing high-quality vital signs data for drug development. As the device gains traction, it may also see increased adoption in other regions, potentially influencing global clinical trial practices. The ongoing validation of the device in South Korea and its integration into national health systems could serve as a model for other countries considering similar innovations in healthcare technology.
